Featured

Status

Health Topics

Any Category
Clear Filters

Search Clinical Trials

133 Results
Completed
A Salivary miRNA Diagnostic Test for Autism
The central aim of this project is to validate a panel of expressed microRNA (miRNA) in the saliva of children identified at risk for developing ASD by the MCHAT-R. Further, …
Baylor Role: Collaborator
Completed
A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement
The AUS is the gold standard for treatment of severe SUI, particularly in patients following surgical resection of the prostate for prostate cancer. In fact, severe urinary incontinence can be …
Baylor Role: Collaborator
Completed
Complementary Combination Therapy for Cocaine Dependence
During a screening session participants will provide buccal swab for genetics testing, as preliminary data shows that effects of cocaine and of doxazosin are impacted significantly by the genotype at …
Baylor Role: Lead Sponsor
Completed
Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a
FAST-MAS addresses an important problem and critical barrier to progress in Mood and Anxiety Spectrum Disorders and if the aims of the project are achieved, FAST-MAS could shift scientific knowledge, …
Baylor Role: Collaborator
Withdrawn
Stem Cells for the Improvement of Erectile and Cardiac Function in Aging Men
Baseline assessment of patients will include completion of 6 questionnaires, EKG (electrocardiogram), vision testing using a standard eye chart, markers of endothelial dysfunction hormone evaluation, laboratory blood tests, vital signs, …
Baylor Role: Lead Sponsor
Completed
Aggression Prevention Training for Caregivers of Persons With Dementia (APT)
Eighty percent of PWD have behavioral or psychological disturbances, including 40% that are aggressive behaviors. The prevalence of pain in PWD is about 60%, and it is a strong predictor …
Baylor Role: Lead Sponsor
Completed
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
The primary objective is to investigate whether all doses (0.1 mg/kg, 0.2 mg/kg, 0.5 mg/kg, and 1.0 mg/kg) of ketamine are superior to active placebo (midazolam 0.045 mg/kg) therapy in …
Baylor Role: Collaborator
Completed
Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse
The noradrenergic system, especially the alpha 1-adrenergic receptor, may play an important role in cocaine addiction in humans. Doxazosin is a long-acting and selective alpha 1-adrenergic receptor blocker, which inhibits …
Baylor Role: Collaborator
Active, Not Recruiting
Multicenter Evaluation of Memory Remediation After TBI With Donepezil
BACKGROUND: Memory deficits are among the most common chronic and functionally important consequences of traumatic brain injury (TBI). Basic and clinical research studies suggest that persistent deficits in verbal memory …
Baylor Role: Lead Sponsor
Completed
One-Day Intervention for Depression and Impairment in Migraine Patients
Adults with comorbid depression and migraine will be randomized to a 1-day (6-hour) workshop of Acceptance and Commitment Training + Migraine Education (ACT-ME) or Migraine Education only (MEO). The intervention …
Baylor Role: Lead Sponsor